Welcome to our dedicated page for Immutep news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.
Immutep Limited reports clinical and corporate developments as a clinical-stage biotechnology company developing Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases. Its updates center on eftilagimod alfa (efti), a LAG-3 immunotherapy evaluated in cancer studies, and IMP761, a LAG-3 agonist antibody for autoimmune disease.
Recurring company news covers trial results and changes across programs such as TACTI-004, INSIGHT-003 and EFTISARC-NEO, FDA orphan drug designation for efti in soft tissue sarcoma, scientific-conference abstracts, development and commercialization collaborations, quarterly activities reports, cash runway commentary and Nasdaq ADR listing compliance matters.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced a Manufacturing Service Agreement with Northway Biotech to produce its preclinical candidate, IMP761, aimed at autoimmune diseases. Northway will develop a GMP-compliant manufacturing process for IMP761 at its facility in Lithuania, with plans for clinical trials post-preclinical development. IMP761 targets autoimmune memory T cells expressing LAG-3, potentially addressing the root causes of autoimmune diseases. Preclinical results from 2019 indicated its ability to reduce T cell infiltration.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced the treatment of the first five patients in its INSIGHT-003 study, which evaluates a triple combination therapy featuring eftilagimod alpha (efti) alongside chemotherapy and anti-PD-1 therapy. The study, led by Prof. Dr. Salah-Eddin Al-Batran, has reported no new safety signals and is progressing well, with patient recruitment on track. Up to 20 patients with solid tumors will be recruited, assessing safety, tolerability, and initial efficacy, with further results anticipated in 2022.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the successful completion of patient recruitment for the Phase II TACTI-002 study, targeting non-small cell lung cancer (NSCLC) and head & neck squamous cell carcinoma (HNSCC). With 185 patients enrolled across all study parts, recruitment was completed under 12 months, surpassing expectations. Interim data from Part C was presented at the SITC Annual Meeting 2021, with further results anticipated in early 2022. This milestone reflects Immutep's commitment to advancing immunotherapy research in challenging pandemic conditions.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the grant of a new patent from the Chinese Patent Office for its immunotherapy candidate, eftilagimod alpha (efti or IMP321). The patent protects combined therapeutic preparations involving efti and anti-PD-1 or anti-PD-L1 antibodies, expiring on January 8, 2036. This follows similar patents granted in Europe and the U.S. between 2018 and 2021. The patent is exclusively licensed to EOC Pharma, which will pay milestone payments and royalties as efti progresses through trials in China.
Immutep Limited (NASDAQ: IMMP) presented promising data at the SITC Annual Meeting 2021, highlighting significant Overall Survival (OS) improvements in patient subgroups from its AIPAC trial. Key findings indicate a median OS of 22.3 months for patients under 65 and 32.5 months for those with low monocyte counts. The Phase II TACTI-002 study revealed a 29.7% Overall Response Rate (ORR) in second-line head and neck cancer patients. The company’s candidate, efti, continues to show potential for improving quality of life and long-term outcomes in cancer treatment.
Immutep Limited has reported promising results from the TACTI-002 trial, noting an Objective Response Rate (ORR) of 29.7% in patients with second-line head and neck squamous cell carcinoma (HNSCC). This study included 37 patients, with 5 achieving complete responses. Additionally, Immutep will recruit 154 first-line HNSCC patients for the TACTI-003 study to assess ORR as the primary endpoint. Detailed data from the AIPAC trial will be presented in an investor webcast on November 17, 2021.
Immutep Limited announced promising final overall survival (OS) data from its Phase IIb AIPAC trial, indicating a median OS of 20.4 months for patients treated with efti and paclitaxel, compared to 17.5 months with placebo. The trial demonstrated significant survival benefits in predefined patient subgroups: +7.5 months for patients 65 years, +19.6 months for those with low monocytes, and +4.2 months for luminal B cancers. A Phase III trial is planned, focusing on these results, which underline the efficacy of efti as an immunotherapy in metastatic breast cancer.
Immutep Limited (NASDAQ: IMMP) announced the grant of a new patent in China for its lead product candidate, eftilagimod alpha (efti). This patent, numbered ZL 201610221687, protects the use of efti combined with chemotherapy for cancer treatment, expiring on October 3, 2028. This addition to Immutep's patent portfolio follows similar grants in Europe, Japan, and the US. The patent is exclusively licensed to EOC Pharma, which will pay milestone fees and royalties as efti progresses in clinical development.
Immutep Limited (NASDAQ: IMMP) has received positive feedback from the European Medicines Agency (EMA) regarding its clinical development program for eftilagimod alpha (efti), particularly the planned Phase III trial in metastatic breast cancer (MBC). This follows encouraging results from the ongoing Phase IIb AIPAC trial. The EMA's support allows Immutep to proceed with the trial design, which will involve multiple countries. Additional regulatory discussions are ongoing with the US FDA.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced key developments in its clinical trials and financial situation for the quarter ended 30 September 2021. The company received approvals for the Phase IIb TACTI-003 trial and successfully enrolled the first patient in the INSIGHT-003 study. Preparations for a new Phase III trial (AIPAC-003) in metastatic breast cancer are ongoing. Financially, Immutep reported cash receipts of $56k and a cash balance of $106.39 million, enhancing its financial position with cash reach extending to December 2023.